



March 16, 2020

Re: Rejuvenate™ efficacy against SARS-CoV-2, the virus which causes COVID-19 disease

Dear Sir or Madam,

SARS-CoV-2, the causative agent of the ongoing COVID-19 pandemic, is an emerging pathogen; therefore, neither the EPA nor Health Canada have an approved test method for determining or allowing disinfectant efficacy product label claims. In cases of Emerging Pathogens such as SARS-CoV-2, the EPA implements the Emerging Viral Pathogens Guidance for Antimicrobial Products. This guidance utilizes an organism hierarchy to identify effective products for use with emerging pathogens and to permit registrants to make limited statements against such pathogens. Coronaviruses are enveloped viruses, which are among the easiest organisms for disinfectants to kill or inactivate. The following criteria are used to determine efficacy of a disinfectant upon activation of the Emerging Pathogen Rule:

1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (e.g. Poliovirus).

The Rejuvenate™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) fulfill these criteria and are included on the EPA’s List N: Disinfectants for Use Against SARS-CoV-2. Simply search by the EPA Registration Number; 74559-4 for the concentrate, 74559-1 for the ready-to-use and 74559-3 for the premoistened wipes. (<https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>).

The Rejuvenate™ line of disinfectants can be used against SARS-CoV-2 as part of a facility’s COVID-19 infection prevention and control plan on hard, non-porous surfaces. Rejuvenate™ concentrate should be applied at a 1:64 dilution for a contact time of five minutes. Rejuvenate™ ready-to-use liquid and wipes should be applied with a one-minute contact time. Refer to the CDC website at www.cdc.gov/outbreaks/ for additional information.

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at nkenny@virox.com.

Best Regards,

Nicole Kenny, HBSc., Assoc Chem
Vice President, Professional and Technical Services
Virox Technologies Inc.

